VIR insiders executed 10b5-1 sales totaling 524,297 shares in Oct 2025

Rhea-AI Filing Summary

SVF Endurance (Cayman) Ltd and affiliated reporting persons disclosed insider sales of 524,297 shares of Vir Biotechnology, Inc. (VIR) across two dates in early October 2025. The sales occurred on 10/03/2025 and 10/06/2025 at weighted average prices of approximately $5.5553 and $5.6878, respectively, and were executed under a Rule 10b5-1 trading plan established on 09/03/2025. Following these disposals the reporting group beneficially owned 16,159,744 shares.

The filing clarifies that SVF Endurance (Cayman) Limited is the record holder and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited appointed as the alternative investment fund manager responsible for investment decisions.

Positive

• Sales executed under a Rule 10b5-1 plan, indicating pre-arranged trading and potential affirmative defense
• Full disclosure of weighted-average prices with an undertaking to provide per-transaction breakdowns on request

Negative

• Material reduction of position: 524,297 shares sold, which reduces liquidity cushion
• Share price pressure risk from additional plan-driven sales given prices in the low-$5 range

Insights

Corporate Governance Analyst

Insider sales followed a pre-established Rule 10b5-1 plan, reducing the group stake while preserving disclosure transparency.

The sales of 524,297 shares were executed under a documented 10b5-1 plan dated 09/03/2025, which provides an affirmative defense against claims of trading on nonpublic information when the plan meets regulatory conditions. That structure typically indicates pre-planned liquidity rather than opportunistic trading.

Key dependencies include continued compliance with plan terms and the manager's role: SB Investment Advisers (UK) Limited is identified as the AIFM and thus has exclusive decision authority for SVF's holdings; monitor any future Form 4 filings for changes to plan parameters or additional disposals in the coming months.

Equity Markets Analyst

Market impact is likely modest given the trade size versus the fund's residual stake, but the weighted prices show recent trading near the low-$5 range.

The combined disposal of 524,297 shares at weighted averages of $5.5553 and $5.6878 signals executed liquidity at prices between $5.355 and $5.823. The reporting group still holds 16,159,744 shares, indicating the sales were a partial reduction rather than an exit.

Watch subsequent filings over the next 30-90 days for additional plan-driven sales or any amendments that could alter the rate of disposals; near-term share-price sensitivity may increase if further scheduled sell orders are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD.,

190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		S(1)		450,342	D	$5.5553(2)	16,233,699	I	See footnote(3)
Common Stock	10/06/2025		S(1)		73,955	D	$5.6878(4)	16,159,744	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD.,

190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SOFTBANK VISION FUND (AIV M1) L.P.

(Last) (First) (Middle)

1521 CONCORD PIKE

(Street)

WILMINGTON DE 19803

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SB INVESTMENT ADVISERS (UK) LTD

(Last) (First) (Middle)

69 GROSVENOR STREET

(Street)

LONDON X0 W1K 3JP

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.355 to $5.823. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.58 to $5.82. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director	10/07/2025
	SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel	10/07/2025
	SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did insiders of Vir Biotechnology (VIR) sell and when?

Reporting persons sold a total of 524,297 shares on 10/03/2025 and 10/06/2025 under a Rule 10b5-1 plan.

At what prices were the VIR shares sold?

The weighted average prices were approximately $5.5553 for the 10/03/2025 trades and $5.6878 for the 10/06/2025 trades; execution prices ranged from $5.355 to $5.823.

How many Vir shares does the reporting group hold after the sales?

After the reported transactions the group beneficially owned 16,159,744 shares.

Who are the reporting entities for these transactions?

The filings list SVF Endurance (Cayman) Limited, SoftBank Vision Fund (AIV M1) L.P., and SB Investment Advisers (UK) Limited as reporting persons, with SBIA UK appointed as the AIFM.

Were the sales discretionary or part of a trading plan?

The sales were made pursuant to a Rule 10b5-1 trading plan entered into on 09/03/2025, per the Form 4 explanation.